12/02/2026 16:03
Morgan Stanley raised the target price for WuXi Bio (02269) to HKD50 from HKD45 and maintained the "overweight" rating.
The research house said it raises 2026-30 earnings estimates by 4-10% on accelerating revenue growth and margin expansion.
【你點睇？】日本眾議院大選結束，自民黨單獨贏得過半議席，你認為高市此後強勢執政，會否採取激進行動？北京會如何回應？► 立即投票
上一篇新聞︰13/02/2026 14:49 {I-bank focus}BofA lowers Lenovo Group (00992) to HKD9.9
下一篇新聞︰11/02/2026 16:05 {I-bank focus}HSBC starts TravelSky Tech (00696) at HKD12.8
16/02/2026 14:30 {I-bank focus}HSBC lowers Bud APAC (01876) to HKD8.3
13/02/2026 16:07 {I-bank focus}UBS lowers Bud APAC (01876) to HKD8.6
11/02/2026 14:30 {I-bank focus}Daiwa raises Chow Tai Fook (01929) to HKD17
10/02/2026 16:02 {I-bank focus}HSBC lowers Pop Mart (09992) to HKD354
10/02/2026 14:50 {I-bank focus}HSBC raises Tigermed (03347) to HKD64.6
